Clinical Focus ›› 2026, Vol. 41 ›› Issue (9): 859-864.doi: 10.3969/j.issn.1004-583X.2026.09.013
-
Received:2026-07-16Online:2026-09-20Published:2026-09-17
CLC Number:
Cite this article
share this article
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2026.09.013
| [1] | Gish R, Fan JG, Dossaji Z, et al. Review of current and new drugs for the treatment of metabolic-associated fatty liver disease[J]. Hepatol Int, 2024, 18(Suppl 2):977-989. doi: 10.1007/s12072-024-10698-y. |
| [2] | Lago-Sampedro A, Oualla-Bachiri W, García-Serrano S, et al. Protective effect of high adherence to mediterranean diet on the risk of incident type-2 diabetes in subjects with MAFLD: The Di@bet.es Study[J]. Nutrients, 2024, 16(21):3788. doi: 10.3390/nu16213788. |
| [3] | Kim H, Lee DS, An TH, et al. Metabolic spectrum of liver failure in type 2 diabetes and obesity: From NAFLD to NASH to HCC[J]. Int J Mol Sci, 2021, 22(9):4495. doi: 10.3390/ijms22094495. |
| [4] |
Zhang S, Zeng X F, Borné Y, et al. Adherence to the EAT-Lancet reference diet and risk of type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, and their co-occurrence[J]. Food Funct, 2025, 16(17):6773-6785. doi: 10.1039/d4fo05852f.
pmid: 40793982 |
| [5] |
Di Pastena F, Pond G, Tsakiridis EE, et al. Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy[J]. Radiat Oncol, 2024, 19(1): 155.doi: 10.1186/s13014-024-02546-y.
pmid: 39511611 |
| [6] |
Wang D, Day EA, Townsend LK, et al. GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease[J]. Nat Rev Endocrinol, 2021, 17(10): 592-607.doi: 10.1038/s41574-021-00529-7.
pmid: 34381196 |
| [7] | Yang C, Chen H, Huang X, et al. GDF15: An emerging disease target and biomarker of metabolic diseases[J]. J Endocrinol Invest, 2025, 48(11):2563-2576. doi: 10.1007/s40618-025-02636-y. |
| [8] |
Lu JF, Zhu MQ, Xia B, et al. GDF15 is a major determinant of ketogenic diet-induced weight loss[J]. Cell Metab, 2024, 36(2): 454-456.doi: 10.1016/j.cmet.2024.01.004.
pmid: 38325339 |
| [9] | Wang Q, Farhadipour M, Thijs T, et al. Bitter-tasting drugs tune GDF15 and GLP-1 expression via bitter taste or motilin receptors in the intestine of patients with obesity[J]. Mol Metab, 2024, 88: 102002.doi: 10.1016/j.molmet.2024.102002. |
| [10] | Hsu JY, Crawley S, Chen M, et al. Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15[J]. Nature, 2017, 550(7675): 255-259.doi: 10.1038/nature24042. |
| [11] | Olsen OE, Skjærvik A, Størdal B F, et al. TGF-β contamination of purified recombinant GDF15[J]. PLoS One, 2017, 12(11): e0187349.doi: 10.1371/journal.pone.0187349. |
| [12] | Govaere O, Cockell S, Tiniakos D, et al. Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis[J]. Sci Transl Med, 2020, 12(572):eaba4448. doi: 10.1126/scitranslmed.aba4448. |
| [13] | Li D, Zhang H, Zhong Y. Hepatic GDF15 is regulated by CHOP of the unfolded protein response and alleviates NAFLD progression in obese mice[J]. Biochem Biophys Res Commun, 2018, 498(3): 388-394.doi: 10.1016/j.bbrc.2017.08.096. |
| [14] |
Mullican SE, Lin-Schmidt X, Chin CN, et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates[J]. Nat Med, 2017, 23(10): 1150-1157.
doi: 10.1038/nm.4392 pmid: 28846097 |
| [15] | Wang D, Townsend LK, Desormeaux GJ, et al. GDF15 promotes weight loss by enhancing energy expenditure in muscle[J]. Nature, 2023, 619(7968): 143-150.doi: 10.1038/nm.4392. |
| [16] | Chrysovergis K, Wang X, Kosak J, et al. NAG-1/GDF-15 prevents obesity by increasing thermogenesis, lipolysis and oxidative metabolism[J]. Int J Obes (Lond), 2014, 38(12):1555-1564. doi: 10.1038/ijo.2014.27. |
| [17] |
Zhang M, Sun W, Qian J, et al. Fasting exacerbates hepatic growth differentiation factor 15 to promote fatty acid β-oxidation and ketogenesis via activating XBP1 signaling in liver[J]. Redox Biol, 2018, 16:87-96. doi: 10.1016/j.redox.2018.01.013.
pmid: 29482168 |
| [18] |
Zhang Z, Xu X, Tian W, et al. ARRB1 inhibits non-alcoholic steatohepatitis progression by promoting GDF15 maturation[J]. J Hepatol, 2020, 72(5): 976-989.doi: 10.1016/j.jhep.2019.12.004.
pmid: 31857195 |
| [19] |
Kim KH, Kim SH, Han DH, et al. Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice[J]. Sci Rep, 2018, 8(1): 6789. doi: 10.1038/s41598-018-25098-0.
pmid: 29717162 |
| [20] |
Koo BK, Um SH, Seo DS, et al. Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease[J]. Liver Int, 2018, 38(4): 695-705.doi: 10.1111/liv.13587.
pmid: 28898507 |
| [21] | Wang Y, Chen C, Chen J, et al. Overexpression of NAG-1/GDF15 prevents hepatic steatosis through inhibiting oxidative stress-mediated dsDNA release and AIM2 inflammasome activation[J]. Redox Biol, 2022, 52: 102322.doi: 10.1016/j.redox.2022.102322. |
| [22] |
Li X, Huai Q, Zhu C, et al. GDF15 ameliorates liver fibrosis by metabolic reprogramming of macrophages to acquire anti-inflammatory properties[J]. Cell Mol Gastroenterol Hepatol, 2023, 16(5): 711-734.doi: 10.1016/j.jcmgh.2023.07.009.
pmid: 37499753 |
| [23] | Laurens C, Parmar A, Murphy E, et al. Growth and differentiation factor 15 is secreted by skeletal muscle during exercise and promotes lipolysis in humans[J]. JCI Insight, 2020, 5(6):e131870. doi: 10.1172/jci.insight.131870. |
| [24] | Xiong Y, Walker K, Min X, et al. Long-acting MIC-1/GDF15 molecules to treat obesity: Evidence from mice to monkeys[J]. Sci Transl Med, 2017, 9(412):eaan8732. doi: 10.1126/scitranslmed.aan8732. |
| [25] | Wang X, Chrysovergis K, Kosak J, et al. Lower NLRP3 inflammasome activity in NAG-1 transgenic mice is linked to a resistance to obesity and increased insulin sensitivity[J]. Obesity (Silver Spring), 2014, 22(5): 1256-1263. doi: 10.1002/oby.20638. |
| [26] |
Lertpatipanpong P, Lee J, Kim I, et al. The anti-diabetic effects of NAG-1/GDF15 on HFD/STZ-induced mice[J]. Sci Rep, 2021, 11(1): 15027. doi: 10.1038/s41598-021-94581-y.
pmid: 34294853 |
| [27] |
Lee SE, Kang SG, Choi MJ, et al. Growth differentiation factor 15 mediates systemic glucose regulatory action of t-helper type 2 cytokines[J]. Diabetes, 2017, 66(11): 2774-2788.doi: 10.2337/db17-0333.
pmid: 28874416 |
| [28] | Schernthaner-Reiter MH, Itariu BK, Krebs M, et al. GDF15 reflects beta cell function in obese patients independently of the grade of impairment of glucose metabolism[J]. Nutr Metab Cardiovasc Dis, 2019, 29(4):334-342. doi: 10.1016/j.numecd.2018.12.008. |
| [29] | Asrih M, Dusaulcy R, Gosmain Y, et al. Growth differentiation factor-15 prevents glucotoxicity and connexin-36 downregulation in pancreatic beta-cells[J]. Mol Cell Endocrinol, 2022, 541: 111503. doi: 10.1016/j.mce.2021.111503. |
| [30] |
Zhang H, Mulya A, Nieuwoudt S, et al. GDF15 mediates the effect of skeletal muscle contraction on glucose-stimulated insulin secretion[J]. Diabetes, 2023, 72(8): 1070-1082.doi: 10.2337/db22-0019.
pmid: 37224335 |
| [31] | Chang KC, Liu PF, Chang CH, et al. The interplay of autophagy and oxidative stress in the pathogenesis and therapy of retinal degenerative diseases[J]. Cell Biosci, 2022, 12(1): 1.doi: 10.1186/s13578-021-00736-9. |
| [32] | Aguilar-Recarte D, Barroso E, Gumà A, et al. GDF15 mediates the metabolic effects of PPARβ/δ by activating AMPK[J]. Cell Rep, 2021, 36(6): 109501.doi: 10.1016/j.celrep.2021.109501. |
| [33] | Li J, Yang L, Qin W, et al. Adaptive induction of growth differentiation factor 15 attenuates endothelial cell apoptosis in response to high glucose stimulus[J]. PLoS One, 2013, 8(6): e65549. doi: 10.1371/journal.pone.0065549. |
| [34] |
Ray N, Park SJ, Jung H, et al. Stress-responsive Gdf15 counteracts renointestinal toxicity via autophagic and microbiota reprogramming[J]. Commun Biol, 2023, 6(1): 602.doi: 10.1038/s42003-023-04965-1.
pmid: 37270567 |
| [35] |
Kim J, Kim SH, Kang H, et al. TFEB-GDF15 axis protects against obesity and insulin resistance as a lysosomal stress response[J]. Nat Metab, 2021, 3(3): 410-427.doi: 10.1038/s42255-021-00368-w.
pmid: 33758420 |
| [36] | Wang Y, Chen J, Sang T, et al. NAG-1/GDF15 protects against streptozotocin-induced type 1 diabetes by inhibiting apoptosis, preserving beta-cell function, and suppressing inflammation in pancreatic islets[J]. Mol Cell Endocrinol, 2022, 549: 111643.doi: 10.1016/j.mce.2022.111643. |
| [37] | Chen J, Peng H, Chen C, et al. NAG-1/GDF15 inhibits diabetic nephropathy via inhibiting AGE/RAGE-mediated inflammation signaling pathways in C57BL/6 mice and HK-2 cells[J]. Life Sci, 2022, 311(Pt A): 121142.doi: 10.1016/j.lfs.2022.121142. |
| [38] | Jung SB, Choi MJ, Ryu D, et al. Reduced oxidative capacity in macrophages results in systemic insulin resistance[J]. Nat Commun, 2018, 9(1): 1551.doi: 10.1038/s41467-018-03998-z. |
| [39] | Sjøberg KA, Sigvardsen CM, Alvarado-Diaz A, et al. GDF15 increases insulin action in the liver and adipose tissue via a β-adrenergic receptor-mediated mechanism[J]. Cell Metab, 2023, 35(8): 1327-1340.e5. doi: 10.1016/j.cmet.2023.06.016. |
| [40] | Jurado-Aguilar J, Barroso E, Bernard M, et al. GDF15 activates AMPK and inhibits gluconeogenesis and fibrosis in the liver by attenuating the TGF-β1/SMAD3 pathway[J]. Metabolism, 2024, 152: 155772.doi: 10.1016/j.metabol.2023.155772. |
| [41] | Klein AB, Nicolaisen TS, Johann K, et al. The GDF15-GFRAL pathway is dispensable for the effects of metformin on energy balance[J]. Cell Rep, 2022, 40(8): 111258.doi: 10.1016/j.celrep.2022.111258. |
| [42] | Aguilar-Recarte D, Barroso E, Zhang M, et al. A positive feedback loop between AMPK and GDF15 promotes metformin antidiabetic effects[J]. Pharmacol Res, 2023, 187: 106578.doi: 10.1016/j.phrs.2022.106578. |
| [43] | Patel S, Haider A, Alvarez-Guaita A, et al. Combined genetic deletion of GDF15 and FGF21 has modest effects on body weight, hepatic steatosis and insulin resistance in high fat fed mice[J]. Mol Metab, 2022, 65: 101589.doi: 10.1016/j.molmet.2022.101589. |
| [44] | Zhang Y, Zhao X, Dong X, et al. Activity-balanced GLP-1/GDF15 dual agonist reduces body weight and metabolic disorder in mice and non-human primates[J]. Cell Metab, 2023, 35(2): 287-298.e4.doi: 10.1016/j.cmet.2023.01.001. |
| [45] | Richter MM, Kemp IM, Heebøll S, et al. Glucagon augments the secretion of FGF21 and GDF15 in MASLD by indirect mechanisms[J]. Metabolism, 2024, 156: 155915.doi: 10.1016/j.metabol.2024.155915. |
| [46] |
Breit SN, Manandhar R, Zhang HP, et al. GDF15 enhances body weight and adiposity reduction in obese mice by leveraging the leptin pathway[J]. Cell Metab, 2023, 35(8): 1341-1355.e3. doi: 10.1016/j.cmet.2023.06.009.
pmid: 37433299 |
| [1] | . [J]. Clinical Focus, 2026, 41(4): 352-362. |
| [2] | . [J]. Clinical Focus, 2025, 40(12): 1130-1135. |
| [3] | Zhao Xueting, Bai Jiawen, Sun Jun. Analysis of risk factors for liver fibrosis in metabolic dysfunction-associated fatty liver disease and construction of a nomogram [J]. Clinical Focus, 2025, 40(5): 417-422. |
| [4] | Tong Mingxia, Chen Ke, Xiang Xiaocong, Zhou Lifeng. Analysis of lean metabolic-associated fatty liver disease among young and middle-aged people and its risk factors [J]. Clinical Focus, 2025, 40(2): 128-132. |
| [5] | Sun Ya, Yang Shuang. Value of ultrasound-guided attenuation parameter in the quantitative assessment of hepatic steatosis [J]. Clinical Focus, 2025, 40(2): 158-161. |
| [6] | Gou Caixia, Zhang Jie, Baoyixiamu·Ababaikeli , Wang Yiming, Yao Lei, Zheng Rongjiong, Pan Jinliang, Lu Xiaobo. Analysis of influencing factors of sleep quality and metabolically associated fatty liver disease in the physical examination population [J]. Clinical Focus, 2025, 40(1): 33-38. |
| [7] | . [J]. Clinical Focus, 2023, 38(10): 935-939. |
| [8] | . [J]. Clinical Focus, 2023, 38(6): 559-563. |
| [9] | . [J]. Clinical Focus, 2023, 38(4): 373-376. |
| [10] | Cao Yumeng, Zhang Haiyan, Liu Lixin. Correlation between pathological changes and serum ferritin and iron levels in nonalcoholic fatty liver disease: A meta-analysis [J]. Clinical Focus, 2023, 38(3): 197-207. |
| [11] | . [J]. Clinical Focus, 2022, 37(9): 846-854. |
| [12] | Zhang Limin, Sun Jun. Predictive value of FIB-4 in patients with metabolic-associated fatty liver disease complicated with colorectal adenomatous polyps [J]. Clinical Focus, 2022, 37(4): 334-338. |
| [13] | Wen Jie. Correlation analysis between atherogenic index of plasma and nonalcoholic fatty liver disease [J]. Clinical Focus, 2022, 37(1): 35-38. |
| [14] | Li Guohuan, Xie Xu, Huang Zhixia, Zhang Mingye, Tang Yunyun. Quantitative evaluation of transient elastography and acoustic radiation force pulse imaging for non-alcoholic fatty liver disease [J]. Clinical Focus, 2021, 36(6): 535-539. |
| [15] | Zhang Ying, Wang Chunsheng. Effects of Jiangzhi Ligan Granules combined with simvastatin on hepatic biochemical indexes, leptin and adiponectin in treatment of NAFLD [J]. Clinical Focus, 2021, 36(1): 58-61. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||